Decoglurant is primarily investigated for its potential therapeutic applications in the treatment of central nervous system disorders. It acts as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5), which is implicated in various neurological and psychiatric conditions. Research has focused on its use in addressing major depressive disorder (MDD), where modulating glutamate signaling may offer a novel approach to managing symptoms. Additionally, it has been explored for its role in anxiety disorders, schizophrenia, and other conditions linked to glutamate dysregulation. Its ability to target mGluR5 receptors makes it a promising candidate for developing treatments that could provide alternatives to traditional therapies, particularly for patients who do not respond adequately to existing medications. Clinical trials continue to evaluate its efficacy and safety in these areas.